New pill TT-702 for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have an advanced solid tumor (like colorectal, lung, pancreatic, breast, or prostate cancer) that has not responded to standard treatments or no standard treatment is available.
- You can take care of yourself (ECOG score 0–1) and are expected to live at least 12 weeks.
- You must be willing to provide blood and tumor tissue samples, and have fresh biopsies if possible.
- Your blood counts and organ function must be within certain ranges before starting.
- You must have had prior immunotherapy (unless in a special early phase group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a new tablet called GEN-725 for people with advanced solid tumors that have stopped responding to standard treatments or cannot tolerate them. It aims to see if the drug is safe and how it affects the body, and may be an option if you've had prior treatment with PD-1/PD-L1 inhibitors that stopped working at least 6 months ago.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.